SecBot SecBot
Biotech Drug Report Generated Nov 5, 2026

FAYUVI

RARE·Ultragenyx Pharmaceutical Inc.
NEUTRAL
Drug Impact Rating4/10
Trial phase
Approved
Time to market
Already approved and launched commercially as of September 2026.
Why 4/10
FAYUVI was approved by the FDA on September 17, 2026, so the defining binary regulatory event has passed. There is no pending PDUFA or pivotal readout for this drug in the next ~12 months. As an approved, marketed product, the next catalysts are commercial execution (revenue ramp, payer reimbursement) which are not hard binary events. Per the rubric, an approved drug with no pending regulatory decision scores 3-5.
Actionable Insight NEUTRAL

With the approval binary behind it, FAYUVI's investor focus shifts to commercial execution: Q4 2026 and early 2027 revenue disclosures, payer reimbursement decisions, and the number of patients dosed. The stock's 52-week range ($12.73-$39.89) and recent cost-cutting plan suggest the market is pricing in execution risk. Watch for early revenue signals from the Q4 2026 earnings report and any updates on treatment center activations.

Price Chart

Loading chart...

Executive Summary

FAYUVI (rebisufligene etisparvovec, formerly UX111) is a one-time AAV9 gene therapy from Ultragenyx Pharmaceutical (NASDAQ: RARE) that won FDA standard approval on September 17, 2026, as the first-ever treatment for Sanfilippo syndrome type A (MPS IIIA), a fatal pediatric neurodegenerative disease. Priced at $3.95 million per dose, it is Ultragenyx's second gene therapy approval and came with a Priority Review Voucher sold for $203 million. The approval followed a prior rejection in 2025 over manufacturing issues. While the drug addresses a high-unmet-need orphan population and has no direct competition, commercial adoption of a $4 million ultra-rare gene therapy is unproven, and the company is simultaneously cutting costs and pipeline programs to reach profitability by 2027.

How It Works

FAYUVI is a one-time gene therapy that delivers a working copy of the SGSH gene into cells using a harmless AAV9 virus shell. In children with Sanfilippo syndrome type A, a mutation in the SGSH gene causes a toxic sugar molecule (heparan sulfate) to build up in the brain, progressively destroying neurons. The therapy aims to restore the missing enzyme and stop or slow that damage.

Trial Status

FAYUVI was approved by the FDA on September 17, 2026, based on an open-label Phase 1/2/3 trial (NCT02716246 and follow-up studies) in children ages 2-5 with preserved neurodevelopmental function. The trial measured cognitive development against a natural-history control group. Treated patients scored roughly 23.5 points higher on cognitive testing than untreated peers, per published reports. The most common adverse reactions were elevated liver enzymes, nausea, vomiting, and fever.

The Two-Sided Case

▲ Bull Case4
First and only FDA-approved treatment for Sanfilippo syndrome type A, a fatal childhood disease with no prior disease-modifying options, giving it a monopoly position in an ultra-rare indication with 3,000-5,000 patients in the US.
List price of $3.95 million per one-time dose positions it as a potential blockbuster if even a small fraction of eligible patients are treated, and the company received a $203 million Priority Review Voucher upon approval.
Ultragenyx is targeting GAAP profitability in 2027, with Q3 2026 total revenue of $173 million, and FAYUVI plus the earlier gene therapy GENGLYCOS represent new revenue streams beyond the established CRYSVITA franchise.
Multiple large institutional holders (BlackRock, RTW Investments, Vanguard) added or doubled positions in Q2 2026, and the analyst consensus shows 16 Buy/Strong Buy ratings vs 11 Hold, with a mean price target of $26.35 implying ~54% upside from the $17.16 close.
▼ Bear Case4
At $3.95 million list price, commercial adoption faces significant payer access hurdles; ultra-rare gene therapies often see slow uptake as insurers negotiate outcomes-based contracts and treatment centers must be certified.
The drug was rejected by the FDA in 2025 due to manufacturing problems, highlighting manufacturing risk for complex gene therapies, and the open-label single-arm trial design (no placebo control) leaves some efficacy uncertainty.
Ultragenyx recently cut 20% of its workforce, discontinued the GTX-102 Angelman syndrome program, and saw multiple analyst downgrades in September 2026 (JP Morgan, William Blair, Evercore, Baird), reflecting pipeline and commercial concerns.
The stock has fallen sharply from its 52-week high of $39.89 to $17.16, and the company still posted a Q3 2026 net loss of $118 million, with profitability dependent on successful commercial execution of two unproven gene therapy launches.

Upcoming Catalysts

  • Q4 2026 / early 2027 commercial launch revenue updates and payer access progress
  • Expansion into additional international markets (EMA filing)
  • Longer-term follow-up data from the ongoing clinical trial

Source Filing

The SecBot filing or press-release report that triggered this drug report:

Ultragenyx Pharmaceutical Inc. PRESS-RELEASE RARE ·Originating report

Sources · 11

Hover a chip for the title
1 fda.gov2 cnbc.com3 reuters.com4 fiercepharma.com5 biospace.com6 fayuvi.com7 en.wikipedia.org8 fda.gov9 biopharminternational.com10 bioreview.com11 ir.ultragenyx.com